C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
Gurbakhash Kaur, MD, an assistant professor of internal medicine at Mount Sinai Health System, discusses the shifting role of autologous stem cell transplant (ASCT) in an era incr ...
Cure is defined as 5 years in complete remission without any anti-myeloma therapy, timed from treatment end rather than from initial response while still on treatment. Eligibility requires ≥4 ...
The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...
The FDA’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee has voted in favor of ...
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML ...
Shubham Pant, MD, MBBS, discusses the rapidly growing pipeline of RAS-directed agents for patients with pancreatic cancer, building on the momentum of the recent FDA approval of daraxonrasib (Rasonque ...
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...
Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.
NCCN recommends rusfertide across PV risk strata as Category 1, uniquely spanning low- and high-risk disease in the updated ...
Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...
CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers. T-cell–based immunotherapies have transformed the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results